Descrizione del progetto
Un futuro senza attriti per i cateteri
I cateteri sono dispositivi medici di vitale importanza, ma spesso presentano una criticità importante: l’attrito superficiale, che compromette la sicurezza e il comfort dei pazienti. In questo contesto, il progetto ExtruLub, finanziato dall’UE, propone una soluzione per trasformare le prestazioni dei cateteri senza alterarne le proprietà fondamentali. In particolare, l’innovativa tecnologia di estrusione sviluppata dal progetto riduce l’attrito superficiale, genera superfici antimicrobiche e antitrombogeniche e garantisce ai pazienti la massima sicurezza. I produttori di dispositivi otterranno un vantaggio competitivo nel mercato dei cateteri, beneficiando di un’autentica differenziazione del prodotto e della possibilità di conquistare una quota di mercato maggiore. Passando dalla produzione snella a quella a lotti, la tecnologia consentirà di ottenere notevoli risparmi sui costi e, nel complesso, dovrebbe generare milioni di euro di entrate e creare nuovi posti di lavoro.
Obiettivo
ExtruLubTM is an innovative, disruptive extrusion technology applicable across a range of polymer resins, which can change the surface of a catheter without affecting core device properties. The technology fits in the component sub-supply market with an initial global market of €564 mn applicable across all catheter markets, the latter estimated to reach $42.5 bn globally by 2020. From a functional perspective, it has the ability to reduce surface friction, generate protective antimicrobial & antithrombogenic surfaces, passing these benefits and profile reduction to catheters. This functional enhancement safeguards patient safety & commands genuine product differentiation for the device manufacturer, enabling market share. From an economic perspective it facilitates a change from lean to batch manufacturing realising cost containment. For example, an independent study showed ExtruLubTM, employed in the cardiology sector, would reduce costs for the OEM (e.g. Boston Scientific, Medtronic etc.) by 51 %, realising savings for them of ca. €3 mn p.a in one product. DiaNia Technologies will drive the optimisation & advancement of successful Phase 1 results through to commercialisation of ExtruLubTM into selected devices, engaging with a number of successful, leading MedTech companies. In doing so we will utilise direct links with MNCs at the early development phase of their new products. DNT will be taking an export led approach, exploiting the experience of our business development team & board members in expanding our component subsupply business in the MedTech industry. The positive effects of this project include increase in revenues to over €26 MN & employees numbers reaching 38 in YR 5 through the successful rollout of ExtruLubTM Technology.
Campo scientifico
- medical and health sciencesclinical medicineangiologyvascular diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural scienceschemical sciencespolymer sciences
- medical and health sciencesclinical medicinecardiology
- medical and health sciencesmedical biotechnologyimplants
Parole chiave
Programma(i)
- H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme
- H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing
- H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEINST-2-2016-2017
Meccanismo di finanziamento
SME-2 - SME instrument phase 2Coordinatore
H91 Y682 Galway
Irlanda
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.